Literature DB >> 18836994

A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders.

C E Pedreira1, E S Costa, J Almeida, C Fernandez, S Quijano, J Flores, S Barrena, Q Lecrevisse, J J M Van Dongen, A Orfao.   

Abstract

Multiparameter flow cytometry has become an essential tool for monitoring response to therapy in hematological malignancies, including B-cell chronic lymphoproliferative disorders (B-CLPD). However, depending on the expertise of the operator minimal residual disease (MRD) can be misidentified, given that data analysis is based on the definition of expert-based bidimensional plots, where an operator selects the subpopulations of interest. Here, we propose and evaluate a probabilistic approach based on pattern classification tools and the Bayes theorem, for automated analysis of flow cytometry data from a group of 50 B-CLPD versus normal peripheral blood B-cells under MRD conditions, with the aim of reducing operator-associated subjectivity. The proposed approach provided a tool for MRD detection in B-CLPD by flow cytometry with a sensitivity of < or =8 x 10(-5) (median of < or =2 x 10(-7)). Furthermore, in 86% of B-CLPD cases tested, no events corresponding to normal B-cells were wrongly identified as belonging to the neoplastic B-cell population at a level of < or =10(-7). Thus, this approach based on the search for minimal numbers of neoplastic B-cells similar to those detected at diagnosis could potentially be applied with both a high sensitivity and specificity to investigate for the presence of MRD in virtually all B-CLPD. Further studies evaluating its efficiency in larger series of patients, where reactive conditions and non-neoplastic disorders are also included, are required to confirm these results.

Entities:  

Mesh:

Year:  2008        PMID: 18836994     DOI: 10.1002/cyto.a.20638

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  13 in total

Review 1.  Prevalence of monoclonal B-cell lymphocytosis: a systematic review.

Authors:  Youn K Shim; Dannie C Middleton; Neil E Caporaso; Jane M Rachel; Ola Landgren; Fatima Abbasi; Elizabeth S Raveche; Andy C Rawstron; Alberto Orfao; Gerald E Marti; Robert F Vogt
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

2.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

Review 3.  Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

Authors:  Dario Campana
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

4.  Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.

Authors:  Prisca Theunissen; Ester Mejstrikova; Lukasz Sedek; Alita J van der Sluijs-Gelling; Giuseppe Gaipa; Marius Bartels; Elaine Sobral da Costa; Michaela Kotrová; Michaela Novakova; Edwin Sonneveld; Chiara Buracchi; Paola Bonaccorso; Elen Oliveira; Jeroen G Te Marvelde; Tomasz Szczepanski; Ludovic Lhermitte; Ondrej Hrusak; Quentin Lecrevisse; Georgiana Emilia Grigore; Eva Froňková; Jan Trka; Monika Brüggemann; Alberto Orfao; Jacques J M van Dongen; Vincent H J van der Velden
Journal:  Blood       Date:  2016-11-30       Impact factor: 22.113

5.  Minimal residual disease.

Authors:  D Campana
Journal:  Leuk Suppl       Date:  2012-08-09

Review 6.  Minimal residual disease quantitation in acute myeloid leukemia.

Authors:  David Shook; Elaine Coustan-Smith; Raul C Ribeiro; Jeffrey E Rubnitz; Dario Campana
Journal:  Clin Lymphoma Myeloma       Date:  2009

7.  Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.

Authors:  Arjan A van de Loosdrecht; Canan Alhan; Marie Christine Béné; Matteo G Della Porta; Angelika M Dräger; Jean Feuillard; Patricia Font; Ulrich Germing; Detlef Haase; Christa H Homburg; Robin Ireland; Joop H Jansen; Wolfgang Kern; Luca Malcovati; Jeroen G Te Marvelde; Ghulam J Mufti; Kiyoyuki Ogata; Alberto Orfao; Gert J Ossenkoppele; Anna Porwit; Frank W Preijers; Stephen J Richards; Gerrit Jan Schuurhuis; Dolores Subirá; Peter Valent; Vincent H J van der Velden; Paresh Vyas; August H Westra; Theo M de Witte; Denise A Wells; Michael R Loken; Theresia M Westers
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

8.  Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping.

Authors:  E S Costa; C E Pedreira; S Barrena; Q Lecrevisse; J Flores; S Quijano; J Almeida; M del Carmen García-Macias; S Bottcher; J J M Van Dongen; A Orfao
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

9.  Measurements of treatment response in childhood acute leukemia.

Authors:  Dario Campana; Elaine Coustan-Smith
Journal:  Korean J Hematol       Date:  2012-12-24

Review 10.  EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols.

Authors:  T Kalina; J Flores-Montero; V H J van der Velden; M Martin-Ayuso; S Böttcher; M Ritgen; J Almeida; L Lhermitte; V Asnafi; A Mendonça; R de Tute; M Cullen; L Sedek; M B Vidriales; J J Pérez; J G te Marvelde; E Mejstrikova; O Hrusak; T Szczepański; J J M van Dongen; A Orfao
Journal:  Leukemia       Date:  2012-09       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.